Pim Mutsaers

12PUBLICATIONS
62CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesLanguage documentation and descriptionAllergyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 15, 2026
Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.

|Apr 27, 2026
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

|Jul 07, 2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Manali Kamdar, Scott R Solomon, Jon Arnason

|Jan 27, 2025
Single-center off-label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy.

Yvonne Veltman, Anna M Aalbers, Maud A W Hermans

|Jul 23, 2024
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.

Anne Mea Spanjaart, Per Ljungman, Gloria Tridello

|Nov 25, 2023
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.

Janneke W de Boer, Kylie Keijzer, Elise R A Pennings

Pageof 2

Frequent Collaborators

5 joint publications

Joost S P Vermaat

4 joint publications

Margot Jak

4 joint publications

Tom van Meerten

4 joint publications

Elise R A Pennings